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Androgen deprivation therapy (ADT) for prostate carcinoma (PCa) may cause cardiometa-
bolic complications unless intermittent androgen blockade (IAB) is instituted. An 80-year-old
caucasian man was diagnosed intermediate grade (Gleason 4+ 3) PCa and was treated
with continuous ADT with triptorelin plus bicalutamide. After 6months of treatment, he
experienced an acute myocardial infarction and 1month after hospitalization he came to
our outpatient clinic for fatigue, weight gain, and hyperglycemia. Due to iatrogenic hypog-
onadism, we decided to proceed with IAB, but after 3months ADT withdrawal his serum
testosterone (T) was still 0.5 ng/mL. Due to very low concomitant PSA levels (0.1 ng/mL)
he was then proposed intermittent T-gel supplementation (Tostrex®) which was initiated
according to the following scheme: 6months on and 3months off. T-gel dose was titrated
tri-weekly in order to achieve T plasma levels below 3.49 ng/mL. After 6months on, his
serumT raised to a mean value of about 2.0 ng/mL without increments in PSA. After over-
all 12months on, his serum T peaked to a mean value of 3.0 ng/mL while a delay in PSA
rise was seen after 24months (0.6 ng/mL) but remained stable until the last observation
carried forward (LOCF), at 45months. No clinical and biochemical PCa progression were
observed at LOCF. Reversion of iatrogenic metabolic syndrome started after 6months of
T supplementation without using any add-on treatment. This case provides support that
once regression of PCa growth is attained,T supplementation may be administered in well
differentiated PCa, especially if IAB is not successful in reverting iatrogenic hypogonadism
and its associated cardiac and metabolic complications.
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CASE PRESENTATION
An 80-years-old caucasian man (B.F.) with localized prostate car-
cinoma (PCa; Gleason score 4+ 3; stage pT1c) that was treated
with androgen deprivation therapy (ADT) with triptorelin plus
bicalutamide from 6months was referred to our outpatient clinic
for recent onset of fatigue,weight gain, and hyperglycemia. Hewas
taking Suprefact®1 injection every 3months combined with oral
Casodex® 50mg daily. Before and after 6months of ADT, his PSA
dropped from 5.4 (free PSA= 0.81 ng/mL; ratio= 0.15%) to 0.1
while testosterone (T) dropped from3.7 to 0.8 ng/mL, respectively;
plasma LH level before treatment was normal (2.4 IU/L). As a
result of this treatment,he experiencedhospitalization formyocar-
dial ischemia and underwent a revascularization procedure. Once
discarded with speciﬁc therapy (low dose aspirin, angiotensin
receptor blocker plus thiazides, and simvastatin 40mg/day), he
noted the appearance of progressive fatigue, loss of memory, dys-
pnea, tachycardia, weight gain (increase in waist circumference
about two sizes), and diffuse bone pain. He was admitted at
our outpatient clinic with the diagnosis of metabolic syndrome
(Table 1) and iatrogenic hypogonadism and was prescribed a
Whole Body Scintiscan that showed the absence of distant metas-
tases from PCa. According to patient’s Framingham’s score, the
10 years estimated global cardiovascular risk was >30% so that
intermittent androgen blockade (IAB) was recommended in order
to minimize further increase in cardiovascular risk. However,
3months after ADT withdrawal, the patient still complained same
symptoms and his T plasma levels were still to 0.5 ng/mL, with an
LH of 0.1 IU/L. Testicular size was reduced (6mL bilaterally) and
digital rectal examination revealed enlarged prostate with a pal-
pable nodule (primary tumor) that had been already evidenced
at ultrasound diagnosis of PCa without any change in size (2 cm
diameter). Thus, add-on treatment with T supplementation was
advised prior signing a detailed informed consent and the warn-
ing the patient on a possible progression of PCa after commencing
treatment. Accordingly, same warning regarding the progression
of atherosclerosis in severe hypogonadal patients and consequent
increased mortality risk was acknowledged. We decided to use T-
gel 2% (Tostrex®) because of the possibility to titrate the dosage
every 2–3weeks. The patient was started with a dose of 2 puff/day
and total T and PSA were evaluated at 8:00 a.m. every 21 days,
before the application of gel on samemorning (mean dose admin-
istered during the observation period was 2.2 puff/day equaling
22mg/day). After 6months from commencing treatment, glico-
metabolic parameters returned to normal (Table 1), as expected
from the time course of T actions on target organs (Saad et al.,
2011).We decided to maintain his plasma T level below 3.5 ng/mL
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because of consistency with biological effects on target organs as
expected from delta increase from patients’ baseline levels after
ADT. After 30months, PSA peaked to 0.6 ng/mL then remaining
stable throughout the entire period of observation (Figure 1) and
prostate gland did not show further enlargements as suggested
by control TC (data not shown). According to our previous data
(Aversa et al., 2012), the patient was osteopenic at baseline and an
increase inbonemineral density after 3 yearswasdocumented irre-
spective from vitaminD supplementation (Table 1),with reported
improvement in bone pain commencing after 1 year. At present,
the follow-up carried out at 45months shows no further incre-
ments in PSA and no progression of PCa and the patient is still on
intermittent T-gel supplementation.
BACKGROUND
Testosterone is the fundamental steroid hormone that drives
prostate growth but there is no proven evidence that T treat-
ment may convert subclinical PCa to clinically detectable PCa
(Rhoden and Averbeck, 2009; Jannini et al., 2011). After 3- to 6-
months of treatment,ADT is known to causemetabolic imbalance,
i.e., increase in fat mass, insulin resistance, hyperlipidemia, meta-
bolic syndrome (Braga-Basaria et al., 2006), and/or full-blown
diabetes mellitus, loss of bone mass, and fractures (Grossmann
and Zajac, 2011), as well as increased cardiovascular risk, ane-
mia, and loss of muscle (Punnen et al., 2011). All these metabolic
changes put patients at an increased risk of cerebrovascular events,
such as ischemic strokes and transient ischemic attacks, causing a
signiﬁcant increased risk of cardiovascular death (Levine et al.,
2010). T is largely metabolized into its more potent effector, dihy-
drotestosterone (DHT), which promotes cellular proliferation of
prostatic epithelium (Hsing, 2001). Results from the Prostate Can-
cer Prevention Trial indicated that inhibition of the conversion of
T to DHT by ﬁnasteride reduced the occurrence of prostate cancer
by approximately 25%during a 7-year follow-up; although the risk
of high-grade tumors was higher in the treated group than in the
untreated group (Canby-Hagino et al., 2007). The evidence that
prostate cancer development has a hormonal component comes
from a large range of sources, including the historical observa-
tion that most PCa respond to ADT until they invariably estab-
lish an androgen-independent growth mechanism, leading to a
more aggressive, castrate-resistant phenotype (Lonergan and Tin-
dall, 2011). The potential mechanisms involving the genesis and
growthof androgen-independent PCa include super-expressionor
mutation of the androgen receptor (AR), which could determine
resistance to the anti-androgenic therapy.However,most advanced
PCa have no mutations or ampliﬁcations of the AR, suggesting a
potential role of non-androgenic growth factors, such as epidermal
growth factor (EGF), transforming growth factor alpha, insulin-
like growth factor (IGF-1), and ﬁbroblast growth factor. These
factors, and their receptors like EGFR (HER-1) and HER-2/neu,
may contribute to the proliferation and growth of prostate cancer
through paracrine or autocrine mechanisms (Neto et al., 2010).

















Tot chol (mg/dl) 248 223 211 201 214 203 205 210 203
HDL (mg/dl) 25 35 39 41 43 38 41 40 41
TRG (mg/dl) 170 158 139 136 123 127 121 129 133
LDL (mg/dl) 189 166 144 120 146 139 140 144 135
HOMA-IR 3.4 3 2.6 2.4 2.3 2.4 2.5 2.4 2.4
Glucose (mg/dl) 123 119 110 102 95 97 94 93 96
T score lumbar −2.3 ND ND ND −2.1 ND −1.9 −1.8 ND
T score hip −2.5 ND ND ND −2.2 ND −1.8 −1.7 ND
WC (cm) 106 102 98 99 99 97 98 98 98
LOCF, last observation carried forward, WC, waist circumference.
FIGURE 1 |Testosterone and PSA course during 3 years follow-up.
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Recently a collaborative analysis of 18 prospective studies on the
associations between endogenous hormone concentrations and
PCa risk indicates that the circulating concentrations of androgens
or estradiol do not appear to be associated with the risk of prostate
cancer. Nowadays, a history of PCa is an absolute contraindication
to T supplementation therapy (Roddam et al., 2008; Heidenreich
et al., 2011). In the last decade many authors reported their per-
sonal experience in treating men with conﬁned PCa (Kaufman
and Graydon, 2004; Agarwal and Oefelein, 2005) or after radical
prostatectomy (Khera et al., 2009) or heterogeneous populations
of prostate cancer survivors (Leibowitz et al., 2010) with differ-
ent T preparations for different periods of time. Morgentaler and
Traish recently proposed a saturation model that accounts for the
seemingly contradictory results in human PCa studies; They sug-
gested that the changes in serum T concentrations below the point
of maximal androgen–androgen receptor (A–AR) binding elicit
substantial changes in PCa growth, as seen with castration, or
with T administration to previously castrated men. By contrast,
oncemaximalA–ARbinding is attained, the presence of additional
androgen produces little further effect (Morgentaler and Traish,
2009). At present, there is limited experience and controversy
about T use after successful treatment of PCa (Jannini et al., 2011).
This is the ﬁrst interventional report with T supplementation in a
PCa patient who was submitted to prior ADT for localized PCa.
DISCUSSION
Although it is well documented that T administration in castrated
men with advanced or metastatic PCa leads to progression of
disease (Fowler and Whitmore Jr., 1981), this aspect has never
been investigated in patients with localized PCa after ADT with-
drawal. As far as we are aware, this is the ﬁrst report of inter-
mittent T supplementation in the long-term (45months) in a
patient with non-invasive PCa after ADT withdrawal and persis-
tent severe secondary hypogonadism. Despite the long-standing
prohibition against the use of T in men with PCa, preliminary
data from three important publications suggests encouraging
data. A phase-1 study reports no progression of disease due
to T administration after 24months of treatment in men with
low risk castrate-resistant PCa (Szmulewitz et al., 2009). Another
study suggests that even exogenous supraphysiological T levels are
neutral on castrate-resistant PCa progression (Morris et al., 2009).
Morgentaler (2009) reports on a case of PSA decline after 2 years
of T supplementation in a man with untreated PCa. ADT-induced
hypogonadism is an independent risk factor for the development
of insulin resistance/metabolic syndrome, cardiovascular disease,
and bone frailty (Foresta et al., 2011) with an increased male mor-
bidity and mortality. Several clinical trials have examined whether
longitudinal changes in cardiovascular risk factors may translate
into a real increased risk of cardiovascular death. It is presently
unclear whether there is a causal relationship between ADT and
cardiovascular mortality. What is certain is that ADT may affect
cardiovascular mortality in a subset of these study populations
and it may be prudent to carefully consider the potential risks
and beneﬁts before commencing ADT, particularly in patients
with coronary artery disease. Patients with cardiac disease who
initiate ADT should receive particular attention to secondary pre-
ventive interventions (Levine et al., 2010). Keeping in mind these
considerations, and due to the fact that beneﬁts and risks deriv-
ing from ADT in our patient were not evaluated in advance, we
decided to propose IAB in order to minimize further cardiometa-
bolic complications during ADT. Unexpectedly, ADT withdrawal
did not produce physiological increments in plasma T levels so
that we decided to challenge the patient with intermittent T-
gel supplementation considering encouraging results obtained by
other clinical trials. We strictly monitored PSA levels and pro-
gression of disease over a long period of time (45months) and
were able to demonstrate for the ﬁrst time that T supplemen-
tation after ADT did not determine serious adverse events but
long-standing improvements from the metabolic, cardiovascular,
and skeletal standpoints. We are aware that caution is necessary
and conclusions regarding T supplementation in men undergoing
ADT for localized PCa are far to be drawn, as well. However, due
to increased surveillance in higher numbers of men with PCa, the
request for correctionof hypogonadism-related complicationswill
be increasing.We hope thatmulticenter clinical trials investigating
this aspect will be proposed in the near future.
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